AIM
ADPT icon

ARK Investment Management’s Adaptive Biotechnologies ADPT Stock Holding History

ARK Investment Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.8M Sell
2,090,306
-2,663
-0.1% -$40.8K 0.29% 64
2026
Q1 		$29.1M Sell
2,092,969
-45,991
-2% -$733K 0.23% 70
2025
Q4 		$34.7M Sell
2,138,960
-1,026,676
-32% -$16.8M 0.23% 68
2025
Q3 		$47.4M Sell
3,165,636
-850,849
-21% -$10.4M 0.28% 60
2025
Q2 		$46.8M Sell
4,016,485
-3,716,085
-48% -$33.8M 0.34% 48
2025
Q1 		$57.5M Sell
7,732,570
-1,691,504
-18% -$13M 0.58% 36
2024
Q4 		$56.5M Sell
9,424,074
-2,177,060
-19% -$12M 0.47% 38
2024
Q3 		$59.4M Buy
11,601,134
+189,134
+2% +$824K 0.54% 35
2024
Q2 		$41.3M Buy
11,412,000
+850,704
+8% +$2.7M 0.37% 46
2024
Q1 		$33.9M Sell
10,561,296
-2,245,217
-18% -$8.69M 0.23% 63
2023
Q4 		$62.8M Buy
12,806,513
+1,297,205
+11% +$5.92M 0.37% 41
2023
Q3 		$62.7M Buy
11,509,308
+1,055,556
+10% +$6.98M 0.48% 37
2023
Q2 		$70.1M Buy
10,453,752
+1,248,627
+14% +$9.28M 0.46% 35
2023
Q1 		$81.3M Buy
9,205,125
+3,880
+0% +$34.2K 0.56% 32
2022
Q4 		$70.3M Sell
9,201,245
-135,374
-1% -$1.05M 0.61% 33
2022
Q3 		$66.5M Buy
9,336,619
+563,601
+6% +$5.31M 0.46% 40
2022
Q2 		$68.6M Buy
8,773,018
+1,063,352
+14% +$9.35M 0.41% 46
2022
Q1 		$107M Buy
7,709,666
+2,011,798
+35% +$31.6M 0.45% 40
2021
Q4 		$160M Buy
5,697,868
+841,447
+17% +$25.8M 0.48% 42
2021
Q3 		$165M Buy
4,856,421
+489,444
+11% +$17.7M 0.4% 53
2021
Q2 		$178M Buy
4,366,977
+893,067
+26% +$34.7M 0.33% 66
2021
Q1 		$140M Buy
3,473,910
+1,928,207
+125% +$104M 0.28% 74
2020
Q4 		$91.4M Buy
1,545,703
+660,981
+75% +$34.1M 0.24% 75
2020
Q3 		$43M Buy
884,722
+575,584
+186% +$24.2M 0.26% 61
2020
Q2 		$15M Buy
+309,138
New +$11.3M 0.16% 70

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

ARK Investment Management's ADPT Position: Q2 2026 in Review

ARK Investment Management reduced its Adaptive Biotechnologies (ADPT) stake by 0.13% in Q2 2026, selling an estimated $40.8K and leaving 2,090,306 shares worth $44.8M. The position accounts for 0.29% of the portfolio, ranked #64.

ARK Investment Management first reported a position in ADPT in Q2 2020 and has held it in 25 quarters since. The position peaked at $178M in Q2 2021. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • ARK Investment Management held 2,090,306 shares of Adaptive Biotechnologies worth $44.8M as of Q2 2026.
  • ARK Investment Management sold 2,663 Adaptive Biotechnologies shares in Q2 2026, an estimated $40.8K.
  • Adaptive Biotechnologies made up 0.29% of ARK Investment Management's portfolio in Q2 2026, its #64 holding.
  • ARK Investment Management first reported a position in Adaptive Biotechnologies in Q2 2020 and has held it in 25 quarters since.
  • ARK Investment Management's Adaptive Biotechnologies position peaked at $178M in Q2 2021.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on ARK Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.